Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 156 AML
2022-502478-18-00Phase 2Authorised
- Sponsor
- HOVON
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) comparing Gilteritinib arm with Midostaurin arm (2 arms). Primary endpoint: Overall survival. Planned start Dec 2019; status: authorised.
02
Drugs
gilteritinibmidostaurin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2022-502478-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502478-18-00.